Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.

Author:

Presley Carolyn Jean1,Soulos Pamela R.2,Chiang Anne C.1,Longtine Janina A2,Adelson Kerin B.2,Herbst Roy S.2,Nussbaum Nathan C3,Sorg Rachael3,Abernethy Amy Pickar4,Agarwala Vineeta3,Gross Cary Philip2

Affiliation:

1. Yale Cancer Center, New Haven, CT;

2. Yale School of Medicine, New Haven, CT;

3. Flatiron Health, New York, NY;

4. Duke University Medical Center, Duke Cancer Institute, Durham, NC;

Abstract

6563 Background: The use of next generation sequencing (NGS) in patients with advanced non-small cell lung cancer (NSCLC) is increasing. This study explored disparities in the use of NGS testing. Methods: This retrospective observational study utilized Flatiron Health’s longitudinal, demographically and geographically diverse database containing electronic health record data from 191 oncology practices across the U.S. We identified patients diagnosed with advanced (stages IIIB/IV or recurrent) non-squamous NSCLC who received first line treatment and either NGS testing or standard biomarker testing (e.g., EGFR, ALK) alone. NGS included any multi-gene panel testing > 30 genes. Logistic regression modeled the association between patient characteristics and receipt of NGS testing, accounting for clustering of patients by oncology practice. Results: Among 5,688 adults with advanced NSCLC, 4,813 (84.6%) patients received standard biomarker testing alone and 875 (15.4%) patients received NGS testing. The median age of the sample was 67y (IQR: 41-85), the majority was white (63.6%) vs. black (7.5%) vs. unknown (13.4%), and had a history of smoking (79.9%). Among the youngest patients ( < 45y), 31.5% received NGS compared to 11.3% among the oldest (76-85y; P < .001). Approximately 16% of white patients received testing, compared to 11.4% of black patients (P < .001). Patients with Medicaid received testing less often than commercially insured patients (11.7% vs 17.0%; P = .10). Patients had significantly lower odds of receiving NGS testing if they were older (≥75 vs. < 45 years of age; adjusted OR: 0.21, 95% CI: 0.13-0.34), black vs. white race (aOR: 0.63, 95% CI: 0.44-0.90) or were Medicaid vs. commercially insured (aOR: 0.54, 95% CI: 0.30-0.97). Conclusions: Significant age, race, and insurance-related disparities exist in the receipt of NGS testing among patients with advanced lung cancer in real world clinical practice.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3